by MM360 Staff | Jun 2, 2025 | Myeloma News
Source: Pharmacy Times articles Experts discuss BiTE therapy in treating lung cancers, focusing on innovative agents like tarlatamab and amivantimab, and their toxicity management. Read More
by MM360 Staff | Jun 1, 2025 | Myeloma News
Source: Pharmacy Times articles Post Content Read More
by MM360 Staff | Jun 1, 2025 | Myeloma News
Source: Pharmacy Times articles Kausik K. Ray, MD, discussed the importance of early, aggressive, and sustained LDL-C lowering for atherosclerotic cardiovascular disease prevention, highlighting that the magnitude of cardiovascular risk reduction is independent of the...
by MM360 Staff | Jun 1, 2025 | Myeloma News
Source: Pharmacy Times articles Børge G. Nordestgaard, MD, DMSc, discussed the role of remnant cholesterol as an independent risk factor for atherosclerotic cardiovascular disease and the emerging therapies that may help manage residual cardiovascular risk beyond...
by MM360 Staff | Jun 1, 2025 | Myeloma News
Source: Pharmacy Times articles Incretin-based therapies, including GLP-1 and dual GLP-1/GIP receptor agonists, are transforming the management of type 2 diabetes, obesity, and cardiovascular risk. Read More
by MM360 Staff | Jun 1, 2025 | Myeloma News
Source: Pharmacy Times articles Frank Qian, MD, MPH, discusses clinical considerations for omega-3 fatty acid therapy, such as the patient populations who may benefit most and important safety concerns. Read More